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Abstract 
Purpose: To investigate the dosimetric advantage of intensity-modulated radiotherapy 
(IMRT) for whole ventricles (WV) in patients with a localized intracranial germinoma 
receiving induction chemotherapy. Methods and Materials: Data from 12 consecutive 
patients with localized intracranial germinomas who received induction chemotherapy 
and radiotherapy were used. Four-field coplanar three-dimensional conformal 
radiotherapy (3DCRT) and seven-field coplanar IMRT plans were created. In both plans, 
24 Gy was prescribed in 12 fractions for the planning target volume (PTV) involving WV 
and tumor bed. In IMRT planning, optimization was conducted to reduce the doses to the 
organs at risk (OARs) as much as possible, keeping the minimum dose equivalent to that 
of 3DCRT. The 3DCRT and IMRT plans were compared in terms of the dose-volume 
statistics for target coverage and the OARs. Results: IMRT significantly increased the 
percentage volume of the PTV receiving 24 Gy compared with 3DCRT (93.5% vs. 84.
8%; p = 0.007), while keeping target homogeneity equivalent to 3DCRT (p = 0.869). The 
absolute percentage reduction in the irradiated volume of the normal brain receiving 
100%, 75%, 50%, and 25% of 24 Gy ranged from 0.7% to 16.0% in IMRT compared with 
3DCRT (p < 0.001). No significant difference was observed in the volume of the normal 
brain receiving 10% and 5% of 24 Gy between IMRT and 3DCRT. Conformation number 
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was significantly improved in IMRT (p < 0.001). For other OARs, the mean dose to the 
cochlea was reduced significantly in IMRT by 22.3% of 24 Gy compared to 3DCRT 
(p < 0.001). Conclusions: Compared with 3DCRT, IMRT for WV improved the target 
coverage and reduced the irradiated volume of the normal brain in patients with 
intracranial germinomas receiving induction chemotherapy. IMRT for WV with 
induction chemotherapy could reduce the late side effects due to cranial irradiation 
without compromising control of the tumor. 
 
Keywords: Germinoma; Whole ventricular radiotherapy; Radiotherapy, 
Intensity-Modulated; Planning study 
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Introduction 
Radiotherapy is an effective treatment modality in the treatment of intracranial 
germinomas (1). Craniospinal plus boost radiotherapy has achieved high survival rates of 
more than 90% at 10 years (2–4). The achievement of the high survival rate in young 
patients raised the concerns to the potential late side effects of the craniospinal 
radiotherapy such as cognitive impairment, endocrine dysfunction, secondary tumors, 
and occlusion of brain arteries in long-term survivors (5, 6). To resolve them, the 
dose-reduced or irradiated volume-reduced radiotherapy for intracranial germinoma have 
been attempted. In contrast to the poor disease control by small local field radiotherapy or 
intensive chemotherapy alone (7, 8), the radiotherapy involving whole ventricles (WV) 
could reduce the irradiated volume of the brain without compromising disease control. 
The reported overall survival rate was 93.7–100% at 5 years (9, 10) and 91–92% at 10 
years (11, 12). Three-dimensional conformal radiotherapy (3DCRT) for WV could be an 
alternative treatment to craniospinal plus boost radiotherapy in the treatment of localized 
intracranial germinomas.  
The shape of WV is too complex for 3DCRT to deliver a conformal dose to the 
WV. High dose exposure to the brain surrounding the WV was unavoidable in 3DCRT 
technique. Unlike 3DCRT, intensity-modulated radiotherapy (IMRT) could deliver a 
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conformal dose to the target volume and spare organs at risk (OARs). The dosimetric 
advantage of IMRT for WV has been investigated by other researchers (13, 14). The 
focused point in their reports was the reduction of the dose to the brain. The effect of 
IMRT on the dose distribution in target was not examined. The effect of IMRT on the 
target coverage is another important issue in the planning study of IMRT because 
adequate dose coverage to WV is indispensable to achieve disease-free rates comparable 
to those of craniospinal radiotherapy (8, 15). It remains unclear whether both an 
improvement in target coverage and OAR-sparing are achievable in IMRT for WV.  
This study included the data of 12 patients suffering from localized intracranial 
germinomas who were treated with radiotherapy after induction chemotherapy in our 
hospital. To evaluate the dosimetric advantages of IMRT for WV, we excluded boost 
radiotherapy from this planning study and compared the plans of 3DCRT and IMRT for 
the WV using dose-volume indices of target coverage and OARs. The aim of this study 
was to determine whether IMRT to the WV can improve target coverage and spare OARs 
in patients with localized intracranial germinomas who have received induction 
chemotherapy, compared with 3DCRT for WV.  
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Materials and Methods 
Eligibility criteria 
Twelve patients underwent radiotherapy following induction chemotherapy for 
localized intracranial germinoma at Kyoto University Hospital between June 2003 and 
March 2010. The mean age was 18.2 (range 5–34) years. The primary sites included five 
suprasellar lesions, four pineal lesions, and three combined pineal and suprasellar lesions. 
All patients were given two or three courses of platinum-based induction chemotherapy. 
Complete remission was confirmed by magnetic resonance imaging (MRI) in all patients, 
before computed tomography (CT) was performed. During the CT simulation study, all 
patients were placed in the supine position with the head tilted forward and immobilized 
with a thermoplastic mask. CT with intravenous contrast material was performed with a 
2.5-mm slice thickness using a LightSpeed RT (General Electric Medical Systems). 
Volume definition 
The CT images were exported into the Eclipse treatment planning system (ver. 
8.6; Varian Medical Systems). In this study, the clinical target volume (CTV) was defined 
as the volume of the tumor bed before induction chemotherapy with a 15-mm margin and 
the third, fourth, and lateral ventricles with a 5-mm margin. The tumor bed was contoured 
on the each slice of the CT images, referring to the MRI taken before induction 
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chemotherapy. The third, fourth, and lateral ventricles were contoured using MRI taken 
between completion of the induction chemotherapy and the CT simulation. The volumes 
of organs at risk (OAR), i.e., the brain, chiasm, optic nerves, lens, pituitary gland, and 
cochlea, were also contoured. The report by Merchant et al. was referred to when 
defining the volume of the cochlea (16). Two radiation oncologists (KS and TM) 
confirmed the contoured volumes. The volume of the tumor bed in the suprasellar region 
was non-uniformly enlarged to exclude bone and sinuses from the CTV. The planning 
target volume (PTV) was defined as an additional 5-mm margin around the CTV. The 
mean volumes of the tumor bed, WV, PTV, and normal brain, which was defined as the 
volume of the brain outside the PTV, were 3.6 (range 0.1–15.6), 50.7 (range 33.3–84), 
364.4 (range 295.7–425.0), and 1058.2 (range 759.3–1210.3) mL, respectively. The 
patient characteristics are summarized in Table 1. 
Treatment planning 
All treatment plans were created using 6 MV photon beams from a Varian 
CL21iX linear accelerator and Millennium 120-leaf multileaf collimator (Varian Medical 
Systems). Pencil beam convolution was used for dose calculation, with a 2.5-mm grid 
size. 
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The 3DCRT plans were created with a pair of the coplanar anteroposterior and 
opposed lateral beams centered on the PTV. The PTV was encompassed by irradiation 
fields with 5-mm jaw and leaf margins. In total, 24 Gy in 12 fractions was prescribed to 
the isocenter of the irradiation fields, except for two patients, in whom the isocenter dose 
was reduced so that the maximum dose was less than 107% of the prescribed dose in the 
irradiated volumes. 
In IMRT planning, seven-field coplanar beams were used with fixed gantry angles 
of 0, 55, 105, 155, 205, 255, and 305° using the same isocenter position for the planned 
3DCRT. The Eclipse fluence-based algorithm (Varian) was used in the optimization 
method. Multileaf collimator leaf sequences were generated using the dynamic sliding 
window technique. The planning goals of IMRT were to reduce the doses to the OARs, to 
below the doses seen with 3DCRT, while keeping the minimum target coverage 
equivalent to that planned with 3DCRT (Table 2). We defined the dose encompassing 
99% of the PTV volume (D99%) as a surrogate index for the minimum dose to the PTV. 
Optimization was conducted as follows: the maximum dose (Dmax) to the PTV was 
reduced to less than 107% of the prescribed dose, keeping the equivalent D99% to the 
PTV in 3DCRT. Dmax to the normal brain and the irradiated volume of the normal brain 
were reduced as far as the optimization did not ruin the target coverage. The dose 
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reduction to the OARs other than to the normal brain was a lower priority than the target 
coverage and the normal brain sparing in the optimization. 
Assessment of endpoints 
The dose indices used to compare 3DCRT with IMRT were selected by referring 
to the recommendations for documenting IMRT treatments by the American Society for 
Radiation Oncology workgroup (17). To evaluate the target coverage, Dmax, the dose 
covering 1% of the structure volume (D1%), mean dose (Dmean), the dose that covers 95% 
of the structure volume (D95%), minimum dose (Dmin), and homogeneity index (HI = 
Dmax/Dmin) were used. The doses to the normal brain were assessed using Dmax, D1%, and 
Dmean. The irradiated volume of the normal brain was evaluated using the percentages of 
the volume of the normal brain receiving 100, 75, 50, 25, 10, and 5% of the prescribed 
dose (V100%, V75%, V50%, V25%, V10%, and V5%, respectively). The conformation 
number (CN) in plans of 3DCRT and IMRT was calculated. CN was defined as follows; 
CN = (TVRI/TV)  (TVRI/VRI) where TVRI = target volume covered by the reference 
isodose, TV = target volume and VRI = the volume of the reference isodose (18). 95% 
isodose was used for the reference isodose. The CN ranges from 0 to 1, where 1 is ideal 
value and 0 is least. The doses to the OARs were evaluated using Dmax and Dmean.  
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Statistical analyses 
The paired t-test was used to compare the dose-volume indices of the PTV and 
OARs between 3DCRT and IMRT. All statistical tests were two sided and a p value of 
less than 0.05 was considered to indicate statistical significance. The statistical analyses 
were conducted using GraphPad Prism (ver. 5.03; GraphPad Software). 
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Results 
The CT images showing the dose distributions of 3DCRT and IMRT for a 
representative patient are shown in Figure 1.   
PTV coverage 
The mean D99% to the PTV was 97.8% of the prescribed dose (range 95.8–99.0) 
in all plans. V100% of the PTV was significantly higher in IMRT than that in 3DCRT 
(93.5% vs. 84.8%; p = 0.007). No significant difference was observed in HI, Dmin to the 
PTV, or Dmax to the PTV between 3DCRT and IMRT (p = 0.869, 0.616, and 0.058, 
respectively). D1%, D95%, and Dmean to the PTV were significantly higher in IMRT than 
in 3DCRT (p = 0.012, <0.001, and 0.002, respectively). The absolute differences in D1%, 
D95%, and Dmean between 3DCRT and IMRT were from 0.7% to 1.4% of the prescribed 
dose (Table 3). Figure 2(a) shows the mean dose-volume histogram (DVH) of the PTV. 
The mean DVH in 3DCRT had a relatively wider shoulder for the PTV than that seen in 
IMRT.  
Sparing the volume of the normal brain and the OARs 
D1% and Dmean to the normal brain were significantly lower in IMRT than in 
3DCRT by 1.8% and 6.0% of the prescribed dose, respectively (p < 0.001; Table 3). The 
irradiated volume of the normal brain was reduced throughout the low-to-high dose areas 
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in the mean DVH of the normal brain (Figure 2(b)). V100%, V75%, V50%, and V25% of 
the normal brain were reduced significantly in IMRT versus 3DCRT (4.9% vs. 20.9%, 
36.2% vs. 47.3%, 73.0% vs. 80.0%, and 85.0% vs. 85.7%, respectively; all p < 0.001). 
No significant difference was observed in V10% or V5% of the normal brain between 
IMRT and 3DCRT (93.8% vs. 93.9%, 89.7% vs. 89.9%; p = 0.901 and 0.284, 
respectively). The CN was smaller in 3DCRT than IMRT (0.48 vs. 0.70; p < 0.001). Dmax 
and Dmean to the cochlea were significantly lower in IMRT than in 3DCRT, by 7.9% and 
22.3% of the prescribed dose, respectively. For the other OARs, small differences were 
observed between 3DCRT and IMRT, from 0.6 to 4.9% of the prescribed dose (Table 4). 
The mean monitor units to deliver a 2.0-Gy fraction were 249 (range 240–254) in 3DCRT 
and 980 (range 806–1149) in IMRT. 
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Discussion 
We found that compared with 3DCRT, IMRT for WV improved the target 
coverage and reduced the dose to the normal brain and cochlea in patients with localized 
intracranial germinomas receiving induction chemotherapy. Only small differences were 
observed for doses distributed to other OARs. As expected, a larger number of monitor 
units was needed in the plans for IMRT.  
Comparison with the reported target coverage 
In this study, V100% of the PTV was higher in IMRT than in 3DCRT, while 
keeping the equivalent minimum dose coverage and homogeneity seen in 3DCRT. 
Previous planning studies of IMRT for WV (Table 5), emphasized the dosimetric 
advantage, such as the reduction of the irradiated brain volume, but did not examine the 
dosimetric influences on target coverage (13, 14). Based on our literature search, ours is 
the first reported planning study to indicate that IMRT for WV improves target coverage 
and spares OARs.  
IMRT spares OARs, but may reduce target homogeneity as a trade-off (19, 20). 
This means that IMRT delivers lower minimum and higher maximum doses to the target 
than 3DCRT. In dose- and volume-reduced radiotherapy for intracranial germinomas, a 
lower minimum dose to WV is undesirable because inadequate doses delivered area in 
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WV result in a higher rate of regional recurrence (8, 15). In the study of recurrence pattern 
in 60 patients with intracranial germinoma who received chemotherapy with limited field 
radiotherapy, most of the recurrences were observed in inadequately dose-delivered 
ventricular area (8 of 10 patients). Five patients experienced a recurrence in the 
presumably 20–36 Gy delivered region of cerebral ventricles (21). In addition to the 
lower minimum dose to the PTV, special consideration may be required for the maximum 
dose to the PTV, because most of the PTV consisted of the volume of the brain after 
induction chemotherapy. The volume of the brain within the PTV ends up receiving a 
higher dose even if IMRT spares the normal brain outside the PTV. For IMRT planning, 
the homogenous dose distribution is both favorable and safer by avoiding unexpected 
side effects to the normal brain. D1% to the PTV was significantly higher in IMRT 
planning than those seen in 3DCRT, but it was a small difference (0.7% of the prescribed 
dose). We believe that the improvement in V100% of the PTV and the normal brain 
sparing were more advantageous clinically than the disadvantage caused by the small 
increase of D1% in the radiotherapy of intracranial germinoma.  
Comparison with reported brain sparing 
Planning studies for IMRT for WV focusing on brain sparing have been reported 
in the treatment of intracranial germinomas. IMRT for WV reduced both the Dmean to the 
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brain and the brain volume that received the high dose. However, the reported 
dose-volume histograms showed that there was an increase in the low-dose irradiated 
brain volume (13, 14). Chen et al. reported that IMRT for WV could reduce the irradiated 
volume of the cerebral hemisphere, even at a low dose (22). They compared IMRT plans 
used clinically with the best 3DCRT plans in the treatment of intracranial germ cell 
tumors. In radiotherapy for intracranial germ cell tumors other than intracranial 
germinomas, boost radiotherapy for the primary lesion was indispensable, in addition to 
radiotherapy for the whole central nervous system, whole brain, or WV (23, 24). The 
study by Chen et al. enrolled patients with intracranial germ cell tumors and their 
planning study included boost radiotherapy. In this study, we focused on the dosimetric 
advantage of IMRT for WV in the treatment of intracranial germinomas, which is the 
most common subset of intracranial germ cell tumors (25). In contrast to the other 
intracranial germ cell tumors, WV radiotherapy without a boost was one of the best 
treatment options that could result in a cure (9). Our study showed that IMRT for WV 
reduced the irradiated volume of the normal brain that received high-to-low dose 
exposure, while achieving target coverage in the treatment of intracranial germinomas 
equivalent to that with 3DCRT. Clinically, the reduction in the volume of the irradiated 
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normal brain can be useful for preserving cognitive function and is not harmful if salvage 
radiotherapy is needed. 
Comparison with reported doses to OARs 
In this study, Dmean to the cochlea was reduced by 22.3% of the prescribed dose in 
IMRT planning compared with that in 3DCRT. A prospective study reported that a dose 
to the cochlea of 35 Gy affected the patient’s hearing (26). The threshold of cochlea 
damage from irradiation was lowered through a combination of platinum analogs (27). 
The dosimetric advantage of sparing the cochlea using 3DCRT or IMRT was shown in 
studies of brain tumor radiotherapy, and was beneficial in reducing hearing deterioration 
(16, 28). In radiotherapy for WV, the cochlea was outside the PTV in all of our patients 
and the dose to the cochlea was reduced in IMRT planning without compromising target 
coverage. We expect that the reduced dose to the cochlea in WV radiotherapy would help 
to spare the hearing of patients with localized intracranial germinomas. 
Raggi et al. reported pituitary gland sparing through a mean reduction of 1 Gy in 
IMRT planning. A dose reduction to the suprasellar region is desirable to maintain the 
function of the hypothalamic-pituitary axis (29). However, the volume of the 
hypothalamus and pituitary gland was included in the PTV in all plans in our study, 
especially when the primary lesion was located in the suprasellar region. Adequate dose 
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delivery to the WV is indispensable for controlling intracranial germinomas (8, 15). In 
our study, dose reduction to the pituitary gland was not prioritized in the optimization 
process. The differences in the doses to the optic nerve, chiasm, and lens between IMRT 
and 3DCRT were small (Table 4) and may be irrelevant clinically.  
Increase in monitor units and associated problems 
Leakage and scattered beams are two important issues in IMRT treatment. To 
perform IMRT, the linear accelerator must be energized for a longer time and more 
monitor units are needed, compared with 3DCRT, when delivering the same dose (30). 
Hall et al. reported that IMRT may increase the incidence of solid cancers because more 
monitor units result in higher total-body low-dose exposure (31, 32). However, Tubiana 
et al. pointed out that the recent biological data were not compatible with “linear no 
threshold” (LNT) relationships and the LNT dose-effect relationship led to an 
overestimation of the carcinogenesis risk of low doses (33, 34). One cohort study of 
secondary solid tumors after radiotherapy indicated that 78% of secondary malignancies 
arose in the central PTV or surrounding area (35). Our results showed that IMRT spares 
the normal brain near the PTV without increasing the low-dose irradiated volume of the 
normal brain. Regarding the issue of secondary malignancies, we believe that the benefits 
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of sparing the volume of the normal brain receiving high doses by using the IMRT 
technique outweigh the disadvantages due to leakage and scattered radiation. 
Limitations of this study 
This study included the 12 consecutive patients with intracranial germinomas who 
were treated in our hospital. Intracranial germinomas are rare tumors (25). If more 
samples were included in this study, statistically significant differences might have be 
observed regarding Dmax to the PTV and Dmax to the normal brain, although the observed 
differences were less than 1.0% of the prescribed dose. The effects on the clinical 
outcomes resulting from these differences may be relatively small, considering the 
contributions of the improved target coverage and sparing of the normal brain. 
In conclusion, IMRT for WV improved target coverage and reduced the irradiated 
volumes of normal brain and the dose to the cochlea compared with 3DCRT without 
increasing low-dose exposure to the normal brain. IMRT for WV could improve local 
tumor control and reduce concerns regarding late side effects resulting from cranial 
irradiation in patients with intracranial germinoma. Our results may facilitate the use of 
IMRT for WV in the treatment of intracranial germinomas. 
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Figure legends 
Figure 1. Multi-plane slices showing the isodose distributions for (a) four-field coplanar 
three-dimensional conformal radiotherapy and (b) seven-field coplanar intensity-modulated 
radiotherapy.  Yellow contour = tumor bed before induction chemotherapy; blue contour = 
whole ventricles; green contour = clinical target volume; red contour = planning target volume. 
 
Figure 2. Mean cumulative dose-volume histograms for (a) PTV and (b) normal brain for 
3DCRT and IMRT. 
Abbreviations: PTV = planning target volume; normal brain = the volume of the brain outside 
the PTV; 3DCRT = four-field coplanar three-dimensional conformal radiotherapy; IMRT = 
seven-field coplanar intensity-modulated radiotherapy. 
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Table 1. Patient characteristics and tumor status 
Gender  
 M 9 
 F 3 
Age (years) 18.2 (range 5–34) 
Primary site            
 Pineal region 4 
 Suprasellar region 5 
 Bifocal region 3 
Tumor bed (mL) 3.6 (range 0.1–15.6) 
Ventricles (mL) 50.7 (range 33.3–84) 
PTV (mL) 364.4 (range 295.7–425.0) 
Normal brain (mL) 1058.2 (range 759.3–1210.3) 
Abbreviations: PTV = planning target volume; normal brain = the volume of the brain outside 
the PTV. 
Table 2. Optimization workflow 
Step 1 
 Reduce the dose to normal brain, keeping the equivalent minimal dose to the PTV 
 Constraints of PTV 
 Minimum dose Achieve the equivalent D99% to the PTV in 3DCRT plans 
 Maximum dose Reduce Dmax to the PTV as much as possible, to at least 
less than 107% of the prescribed dose 
 Constraints of brain 
 Reduce Dmax to the normal brain and the irradiated volume of the normal 
brain as much as possible, while satisfying the constraints of the PTV 
Step 2 
 Reduce the dose to OARs, keeping the constraints of the PTV and normal brain in 
Step 1 
Abbreviations: normal brain = the volume of the brain outside the planning target volume; 
PTV = planning target volume; D99% = the dose that covers 99% of the structure; Dmax = the 
maximum dose to the structure volume; OARs = organs at risk. 
Table 3. Summary of dose-volume histogram analysis of PTV and normal brain: mean value 
(range) 
  3DCRT IMRT Difference p value 
PTV     
 Dmax (%) 105.0 (103.3–107.0) 105.7 (104.6–107.0) +0.7 0.058 
 D1% (%) 103.6 (102.0–105.0) 104.3 (103.3–105.9) +0.7 0.012 
 Dmean (%) 100.7 (98.3–101.6) 102.1 (100.7–104.0) +1.4 0.002 
 D95% (%) 99.1 (96.6–100.2) 100.0 (98.3–101.6) +0.9 < 0.001 
 Dmin (%) 89.6 (85.8–94.1) 89.9 (85.7–93.2) +0.3 0.616 
 V100% (%) 84.8 (64.4–96.2) 93.5 (78.0–98.0) +8.7 0.007 
 HI (%) 1.17 (1.12–1.23) 1.17 (1.13–1.23) 0.0 0.869 
Normal brain     
 Dmax (%) 105.1 (103.9–106.3) 104.4 (102.7–105.7) –0.7 0.065 
 D1% (%) 103.3 (100.8–104.9) 101.5 (99.47–103.5) –1.8 < 0.001 
 Dmean (%) 68.2 (61.20–75.40) 62.2 (55.90–70.00) –6.0 < 0.001 
Conformation number 0.48 (0.43–0.55) 0.70 (0.60–0.76) +0.22 < 0.001 
Abbreviations: PTV = planning target volume; normal brain = the volume of brain outside the 
PTV; 3DCRT = four-field coplanar three-dimensional conformal radiotherapy; IMRT = 
seven-field coplanar intensity-modulated radiotherapy; Dmax = the maximum dose to the 
structure; D1% = the dose that covers 1% of the structure volume; Dmean = the mean dose to 
the structure; D95% = the dose that covers 95% of the structure volume; Dmin = the minimum 
dose to the structure; V100% = the percentage of the structure volume receiving the 
prescribed dose; HI = homogeneity index (Dmax/Dmin); Conformation number = (TVRI/TV)  
(TVRI/VRI) where TVRI = target volume covered by the reference isodose, TV = target volume 
and VRI = the volume of the reference isodose. 95% isodose was selected for the reference 
isodose. 
 
Table 4. Summary of the maximum and mean doses to non-target structures: mean 
value (range)  
  3DCRT IMRT Difference p value 
Cochlea     
 Dmax (%) 99.8 (93.70–102.8) 91.9 (74.10–102.3) –7.9 < 0.001 
 Dmean (%) 94.9 (79.10–100.4) 72.6 (55.40–79.70) –22.3 < 0.001 
Pituitary gland     
 Dmax (%) 100.4 (98.30–101.7) 101.5 (98.90–102.9) +1.1 0.003 
 Dmean (%) 99.9 (97.40–101.3) 98.8 (87.00–101.6) –1.1 0.256 
Optic nerve     
 Dmax (%) 99.9 (94.80–101.5) 101.2 (93.30–103.6) +1.3 0.004 
 Dmean (%) 70.7 (30.90–96.10) 65.8 (25.60–94.70) –4.9 0.039 
Chiasm     
 Dmax (%) 100.5 (98.70–101.8) 101.7 (99.50–103.1) +1.2 0.002 
 Dmean (%) 100.2 (98.30–101.4) 100.8 (97.70–102.5) +0.6 0.077 
Lens     
 Dmax (%) 5.7 (2.40–20.1) 7.0 (2.3–14.1) +1.2 0.266 
 Dmean (%) 3.8 (2.2–9.9) 5.2 (2.10–12.3) +1.4 0.021 
Abbreviations: 3DCRT = four-field coplanar three-dimensional conformal radiotherapy; 
IMRT = seven-field coplanar intensity-modulated radiotherapy; Dmax = the maximum 
dose to the structure; Dmean = the mean dose to the structure. 
Table 5. Published planning studies of intensity-modulated radiotherapy for whole 
ventricles 
 Roberge et al. 
(13) 
Raggi et al. 
(14) 
Chen et al. 
(20) 
Sakanaka 
Number of patients 10 5 10 12 
Histology Germinoma Germinoma ICGCT Germinoma 
Beam arrangement non-coplanar non-coplanar coplanar coplanar 
Number of fields 7 7 5-10 7 
Prescribed dose to WV 
(Gy) 
30 24 25.2-37.5* 24 
PTV  
 D1% or Dmax (%) NA 102-104 NA 104.3 
 Dmean (%) NA 99.6 NA 102 
 D95% (%) NA > 95 NA 99.9 
 D99% or Dmin (%) NA > 92 NA 97.7 
 V100% (%) NA NA NA 93.5 
 HI (%) NA NA NA 1.17 
Normal brain  




NA Decrease in 
IMRT 












Conformation number     
 3DCRT NA NA NA 0.48 
 IMRT NA NA NA 0.7 
Monitor units     










Abbreviations: ICGCT = intracranial germ cell tumor; PTV = planning target volume; 
D1% = the dose that covers 1% of the structure volume; Dmax = the maximum dose to 
the structure, Dmean = the mean dose to the structure; D95% = the dose that covers 95% 
of the structure volume; D99% = the dose that covers 99% of the structure volume; Dmin 
= the minimum dose to the structure; V100% = the percentage of the structure volume 
receiving the prescribed dose; HI = homogeneity index (Dmax/Dmin); normal brain = the 
brain outside the PTV; IMRT = intensity-modulated radiotherapy; Conformation 
number = (TVRI/TV)  (TVRI/VRI) where TVRI = target volume covered by the reference 
isodose, TV = target volume and VRI = the volume of the reference isodose. 95% 
isodose was selected for the reference isodose; 3DCRT = three-dimensional conformal 
radiotherapy; NA = not available.  
*The median prescribed dose for WV was 30.6 Gy (range 25.2-37.5 Gy) and the boost 
for the primary lesion was 16.5 Gy (range 0–23.4 Gy). 
†
The dose-volume comparisons between 3DCRT and IMRT were based on the summed 
plan of radiotherapy for WV and the boost for the primary lesion. 
††
The median value of monitor units to deliver a 1.5 to 2.0-Gy fraction in ten patients. 
§
The mean value of monitor units to deliver a 2.0-Gy fraction in 12 patients. 
